ClinicalTrials.gg
CompletedNCT00508404Updated Nov 19, 2019Results posted

Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer

A Phase 2 interventional study of Panitumumab and FOLFIRI in Metastatic Colorectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
29th of 88
154 · median 70
Started
2007
with 1 other
Phase 2
60 of 90
3 open now
Registered
18th of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 29th largest by enrollment of the 88 interventional ones that give a count, is one of 2 that started in 2007, is one of 60 in phase 2, and was the 18th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

To estimate the effect of KRAS mutation status (Wild-type versus Mutant) on objective response rate and other measures of efficacy for patients treated with panitumumab in combination with a chemotherapy regimen of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line therapy for metastatic colorectal cancer (mCRC).

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with - or cytologically-confirmed adenocarcinoma of the colon and/or rectum.
  • according to modified guidelines.
  • (ECOG) performance status of 0, 1 or 2.
  • Paraffin-embedded tissue or unstained tumour slides from primary or metastatic tumour available for central lab analysis.
  • Adequate haematologic, renal, hepatic and metabolic function.

Exclusion criteria

Exclusion Criteria:

  • Central nervous system .
  • Prior systemic therapy for the treatment of metastatic colorectal carcinoma with the exception of fluoropyrimidine-based chemotherapy given at least six months prior to initiating study treatment.
  • Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (e.g. cetuximab) or treatment with small molecule EGFr tyrosine kinase inhibitors (e.g. erlotinib).
  • Prior radiotherapy within 14 days prior to screening, and for which all signs of early radiological toxicity have not abated.
  • Significant cardiovascular disease including unstable angina or myocardial infarction within six months before initiating study treatment or a history of ventricular arrhythmia.
  • History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest computed tomography (CT scan.
  • Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as > 4 loose stools per day).
  • History of Gilbert's syndrome or dihydropyrimidine deficiency.
  • Known positive test for infection, virus, chronic active infection.
  • Any agent within 30 days before initiation of study treatment.
  • Must not have had a major surgical procedure within 28 days prior to initiation of study treatment.
  • Subject who is pregnant or breast-feeding.
  • Woman or man of not consenting to use adequate precautions during the course of the study and for six months after the last study drug administration for women, and one month for men.

    • Other protocol specified criteria and specific details may apply.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Panitumumab plus FOLFIRI

    Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until diagnosed with radiographic disease progression.

    Drug: Panitumumab · Drug: FOLFIRI

Interventions

  • Administered by intravenous infusion

    Also known as: Vectibix

  • DrugFOLFIRI

    FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments are based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions.

    Time frame: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks

Secondary outcomes

  1. Objective Response by 17 Weeks

    The percentage of participants with a best response of complete response or partial response by Week 17. Disease assessments are based on investigator review of scans using modified RECIST V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders.

    Time frame: Up to Week 17

  2. Disease Control Rate

    The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST v1.0 criteria as assessed by the Investigator. Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline.

    Time frame: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks

  3. Duration of Response

    Duration of response was calculated only for those participants who had a confirmed complete or partial response, and is defined as the time from first confirmed response to first observed progression. For participants who responded and did not progress by the analysis data cut-off date, duration of response was censored at their last evaluable disease assessment date. Duration of response was analyzed using the Kaplan-Meier method.

    Time frame: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.

  4. Time to Initial Objective Response

    Time to response is the time from the date of enrollment to the date of first confirmed complete or partial response. Participants with a best response of stable disease at the analysis data cut-off date were censored at their last assessment of SD and participants with all other categories of best response were censored at the maximum observed time to a first confirmed response among all responders. Time to initial objective response was analyzed using Kaplan-Meier methods.

    Time frame: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.

  5. Progression-free Survival

    Progression-free survival is the time from the date of enrollment to the date of first observed progression or death, whichever comes first. Participants who were alive and did not progress by the analysis data cut-off date were censored at the last evaluable disease assessment date. Progression-free survival was analyzed using Kaplan-Meier methods.

    Time frame: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

  6. Time to Disease Progression

    Time to progression is the time from the enrollment date to the date of first observed progression. For participants who had not progressed by the analysis data cutoff date, time to progressive disease was censored at their last evaluable disease assessment date. Time to disease progression was analyzed using Kaplan-Meier methods.

    Time frame: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

  7. Duration of Stable Disease

    Duration of stable disease was calculated only for participants with a best response of stable disease and is defined as the time from enrollment to first observed PD. For participants who did not progress by the analysis data cut-off date, duration of SD was censored at their last evaluable disease assessment date. Duration of stable disease was estimated using Kaplan-Meier methods.

    Time frame: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.

  8. Time to Treatment Failure

    Time to treatment failure is defined as the time from enrollment to the date the decision was made to end the treatment phase for any reason. For participants who remained in the treatment phase at the analysis data cut-off date, time to treatment failure was censored at the date of their last on-study assessment. Time to treatment failure was analyzed using Kaplan-Meier methods.

    Time frame: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

  9. Time to Disease Relapse Following Surgical Intervention

    Calculated only for those participants who underwent surgical intervention, and defined as the time from the date of first post-intervention radiographic disease assessment to the date of first observed PD. Participants with no post-intervention disease assessment had their time to relapse set to zero and censored in the analysis. Participants that had evidence of progression / recurrence at their first post-intervention disease assessment had a time to relapse of zero. For participants who had not progressed by the analysis data cut-off date, time to relapse was censored at the date of their last evaluable disease assessment. Time to relapse was analyzed using Kaplan-Meier metjhods.

    Time frame: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

  10. Resection Rate

    The percentage of participants who underwent a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease.

    Time frame: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

07

Results

Posted Jan 26, 2016

Participant flow

A total of 169 patients were screened, of whom 154 were enrolled into this study at 36 study centers in Austria, Belgium, France, Germany, and Sweden from 9 May 2007 through 18 June 2008. Results are reported through the primary analysis data cut-off date of 18 June 2009 (12 months after the last patient was enrolled).

Participant flow — Overall Study
MilestonePanitumumab Plus FOLFIRI
Started154
Completed112
Not completed42
Withdrew: Ongoing at data cut-off12
Withdrew: Adverse event2
Withdrew: Death16
Withdrew: Physician decision2
Withdrew: Withdrawal by subject3
Withdrew: Protocol-specified criteria2
Withdrew: Lost to follow-up2
Withdrew: Other - not specified3

Outcome measures

PrimaryObjective Response Rate

Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments are based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions.

Time frame:
Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks
Reported as:
Number · percentage of participants
Objective Response Rate
percentage of participantsWild-type KRASMutant KRAS
Objective Response Rate56.47 (45.28 to 67.20)37.93 (25.51 to 51.63)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Odds ratio (or): 2.12 · 95% CI 1.02 to 4.45The odds ratio is defined as the odds of having an objective response in the KRAS Wild-type group relative to the odds in the KRAS Mutant group.
SecondaryObjective Response by 17 Weeks

The percentage of participants with a best response of complete response or partial response by Week 17. Disease assessments are based on investigator review of scans using modified RECIST V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders.

Time frame:
Up to Week 17
Reported as:
Number · percentage of participants
Objective Response by 17 Weeks
percentage of participantsWild-type KRASMutant KRAS
Objective Response by 17 Weeks49.41 (38.39 to 60.48)34.48 (22.49 to 48.12)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Odds ratio (or): 1.86 · 95% CI 0.88 to 3.93The odds ratio is defined as the odds of having an objective response in the KRAS Wild-type group relative to the odds in the KRAS Mutant group.
SecondaryDisease Control Rate

The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST v1.0 criteria as assessed by the Investigator. Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline.

Time frame:
Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks
Reported as:
Number · percentage of participants
Disease Control Rate
percentage of participantsWild-type KRASMutant KRAS
Disease Control Rate90.59 (82.29 to 95.85)89.66 (78.83 to 96.11)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Odds ratio (or): 1.11 · 95% CI 0.30 to 3.89The odds ratio is defined as the odds of having an objective response in the KRAS Wild-type group relative to the odds in the KRAS Mutant group.
SecondaryDuration of Response

Duration of response was calculated only for those participants who had a confirmed complete or partial response, and is defined as the time from first confirmed response to first observed progression. For participants who responded and did not progress by the analysis data cut-off date, duration of response was censored at their last evaluable disease assessment date. Duration of response was analyzed using the Kaplan-Meier method.

Time frame:
Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
Reported as:
Median · months
Duration of Response
monthsWild-type KRASMutant KRAS
Duration of Response13.0 (9.3 to 13.0)7.4 (5.4 to 8.8)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Hazard ratio (hr): 0.283 · 95% CI 0.130 to 0.614Hazard ratio is presented as Wild-type KRAS:Mutant KRAS. A value \< 1.0 indicates a lower average event rate and longer time to event for Wild-type KRAS relative to Mutant KRAS.
SecondaryTime to Initial Objective Response

Time to response is the time from the date of enrollment to the date of first confirmed complete or partial response. Participants with a best response of stable disease at the analysis data cut-off date were censored at their last assessment of SD and participants with all other categories of best response were censored at the maximum observed time to a first confirmed response among all responders. Time to initial objective response was analyzed using Kaplan-Meier methods.

Time frame:
Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
Reported as:
Median · months
Time to Initial Objective Response
monthsWild-type KRASMutant KRAS
Time to Initial Objective Response3.8 (3.4 to NA)NA (5.5 to NA)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Hazard ratio (hr): 1.642 · 95% CI 0.990 to 2.721Hazard ratio is presented as Wild-type KRAS:Mutant KRAS. A value \< 1.0 indicates a lower average event rate and longer time to event for Wild-type KRAS relative to Mutant KRAS.
SecondaryProgression-free Survival

Progression-free survival is the time from the date of enrollment to the date of first observed progression or death, whichever comes first. Participants who were alive and did not progress by the analysis data cut-off date were censored at the last evaluable disease assessment date. Progression-free survival was analyzed using Kaplan-Meier methods.

Time frame:
From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
Reported as:
Median · months
Progression-free Survival
monthsWild-type KRASMutant KRAS
Progression-free Survival8.9 (7.6 to 14.3)7.2 (5.6 to 7.8)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Hazard ratio (hr): 0.464 · 95% CI 0.306 to 0.703Hazard ratio presented as Wild-type KRAS:Mutant KRAS. A value \< 1.0 indicates a lower average event rate and longer time to event for Wild-type KRAS relative to Mutant KRAS.
SecondaryTime to Disease Progression

Time to progression is the time from the enrollment date to the date of first observed progression. For participants who had not progressed by the analysis data cutoff date, time to progressive disease was censored at their last evaluable disease assessment date. Time to disease progression was analyzed using Kaplan-Meier methods.

Time frame:
From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
Reported as:
Median · months
Time to Disease Progression
monthsWild-type KRASMutant KRAS
Time to Disease Progression11.2 (7.6 to 14.8)7.3 (5.7 to 8.9)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Hazard ratio (hr): 0.395 · 95% CI 0.252 to 0.618Hazard ratio is presented as Wild-type KRAS:Mutant KRAS. A value \< 1.0 indicates a lower average event rate and longer time to event for Wild-type KRAS relative to Mutant KRAS.
SecondaryDuration of Stable Disease

Duration of stable disease was calculated only for participants with a best response of stable disease and is defined as the time from enrollment to first observed PD. For participants who did not progress by the analysis data cut-off date, duration of SD was censored at their last evaluable disease assessment date. Duration of stable disease was estimated using Kaplan-Meier methods.

Time frame:
Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
Reported as:
Median · months
Duration of Stable Disease
monthsWild-type KRASMutant KRAS
Duration of Stable Disease5.9 (5.8 to 7.6)6.1 (4.8 to 7.4)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Hazard ratio (hr): 0.756 · 95% CI 0.400 to 1.430Hazard ratio is presented as Wild-type KRAS:Mutant KRAS. A value \< 1.0 indicates a lower average event rate and longer time to event for Wild-type KRAS relative to Mutant KRAS.
SecondaryTime to Treatment Failure

Time to treatment failure is defined as the time from enrollment to the date the decision was made to end the treatment phase for any reason. For participants who remained in the treatment phase at the analysis data cut-off date, time to treatment failure was censored at the date of their last on-study assessment. Time to treatment failure was analyzed using Kaplan-Meier methods.

Time frame:
From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
Reported as:
Median · months
Time to Treatment Failure
monthsWild-type KRASMutant KRAS
Time to Treatment Failure6.9 (6.2 to 7.6)5.8 (5.3 to 6.8)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Hazard ratio (hr): 0.710 · 95% CI 0.503 to 1.002Hazard ratio is presented as Wild-type KRAS:Mutant KRAS. A value \< 1.0 indicates a lower average event rate and longer time to event for Wild-type KRAS relative to Mutant KRAS.
SecondaryTime to Disease Relapse Following Surgical Intervention

Calculated only for those participants who underwent surgical intervention, and defined as the time from the date of first post-intervention radiographic disease assessment to the date of first observed PD. Participants with no post-intervention disease assessment had their time to relapse set to zero and censored in the analysis. Participants that had evidence of progression / recurrence at their first post-intervention disease assessment had a time to relapse of zero. For participants who had not progressed by the analysis data cut-off date, time to relapse was censored at the date of their last evaluable disease assessment. Time to relapse was analyzed using Kaplan-Meier metjhods.

Time frame:
From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
Reported as:
Median · months
Time to Disease Relapse Following Surgical Intervention
monthsWild-type KRASMutant KRAS
Time to Disease Relapse Following Surgical InterventionNA (NA to NA)NA (NA to NA)
SecondaryResection Rate

The percentage of participants who underwent a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease.

Time frame:
From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
Reported as:
Number · percentage of participants
Resection Rate
percentage of participantsWild-type KRASMutant KRAS
Resection Rate15.12 (8.30 to 24.46)6.78 (1.88 to 16.46)
Statistical analysis
  • Wild-type KRAS vs Mutant KRAS · Difference in rates: 8.34 · 95% CI -4.01 to 19.08

Adverse events

Collected over The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 6.6 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab Plus FOLFIRI—84/154 (54.5%)154/154 (100%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventPanitumumab Plus FOLFIRI
DIARRHOEAGastrointestinal disorders21/154
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders11/154
NEUTROPENIABlood and lymphatic system disorders6/154
VOMITINGGastrointestinal disorders6/154
FATIGUEGeneral disorders5/154
PYREXIAGeneral disorders5/154
DEHYDRATIONMetabolism and nutrition disorders5/154
ABDOMINAL PAINGastrointestinal disorders4/154
CATHETER RELATED COMPLICATIONGeneral disorders4/154
CHEST PAINGeneral disorders4/154
Most frequent other events
Showing 10 of 55
Most frequent other events
EventPanitumumab Plus FOLFIRI
DIARRHOEAGastrointestinal disorders119/154
NAUSEAGastrointestinal disorders85/154
RASHSkin and subcutaneous tissue disorders64/154
DRY SKINSkin and subcutaneous tissue disorders61/154
ACNESkin and subcutaneous tissue disorders55/154
ALOPECIASkin and subcutaneous tissue disorders52/154
NEUTROPENIABlood and lymphatic system disorders50/154
FATIGUEGeneral disorders49/154
CONSTIPATIONGastrointestinal disorders46/154
ASTHENIAGeneral disorders42/154

Baseline characteristics

Age, Continuous
Age, Continuous(years)Panitumumab Plus FOLFIRI
Mean62.7 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab Plus FOLFIRI
Female49
Male105
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Panitumumab Plus FOLFIRI
Black or African American2
Hispanic or Latino1
Japanese1
White or Caucasian150
Kirsten Rat Sarcoma-2 Virus (KRAS) Mutation Status
Kirsten Rat Sarcoma-2 Virus (KRAS) Mutation Status(participants)Panitumumab Plus FOLFIRI
Wild-type KRAS86
Mutant KRAS59
Unevaluable KRAS9
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kohne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2012 Jan;138(1):65-72. doi: 10.1007/s00432-011-1061-6. Epub 2011 Sep 30. PubMed 21960318 ↗
  • Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Banos A, Kohne CH. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer. 2012 Sep 29;12:438. doi: 10.1186/1471-2407-12-438. PubMed 23020584 ↗
  • Taieb J, Geissler M, Rivera F, Karthaus M, Wilson R, Loupakis F, Price T, Tracy M, Burdon P, Peeters M. Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Clin Colorectal Cancer. 2019 Dec;18(4):245-256.e5. doi: 10.1016/j.clcc.2019.07.009. Epub 2019 Jul 29. PubMed 31515083 ↗
  • Kohne CH, Karthaus M, Mineur L, Thaler J, Van den Eynde M, Gallego J, Koukakis R, Berkhout M, Hofheinz RD. Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab. Drugs R D. 2019 Sep;19(3):267-275. doi: 10.1007/s40268-019-0278-8. PubMed 31300973 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2007 to primary completion in Jun 2009, 24 months.

Results were first posted in Jan 2016, 6 years 7 months after primary completion. A results delay was requested in Jul 2010.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 24 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2007
First posted
Jul 30, 2007
StartActual
May 9, 2007
Primary completionActual
Jun 1, 2009
CompletionActual
Jun 12, 2012
Results delay requested
Jul 20, 2010
Results first posted
Jan 26, 2016
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00508404
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 30, 2007
Start date
May 9, 2007
Primary completion
Jun 1, 2009
Completion
Jun 12, 2012
Results posted
Jan 26, 2016
Last update
Nov 19, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion